Aurora (ACB:CSE) Continues Accelerated Growth
Aurora Continues Accelerated Growth
– Momentum Public Relations – Feb. 2, 2016
Aurora Cannabis Inc. (“Aurora” or the “Company”) (CSE:ACB)(OTCQB:ACBFF)(FRANKFURT:21P) (WKN: A1C4WM) is pleased to announce that its wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., a producer and distributor of medicinal cannabis pursuant to the Marihuana for Medical Purposes Regulations (“MMPR”), has registered hundreds of fully authorized medical cannabis clients, crop yields have proven to be 100 percent more productive than forecasted, and the strain selection will expand rapidly this month.
Aurora’s recent crop yielded 1.36 grams per watt, or 1.4 kilograms (3.08 pounds) per light. The facility, with 55,200 square feet of expandable licensed production space, will be running at full capacity by spring 2016, with a demonstrated capability of producing over 7,000 kg of dried cannabis annually.
Furthermore, the Company recently launched its revamped website at www.AuroraMJ.com with a streamlined registration process and user-friendly patient and physician portals. Registrations began January 4th, 2016, with all Aurora strains being priced at $8 per gram, as well as a $5 per gram compassionate pricing standard across all strains.
Three-hundred and ten people became a part of Aurora’s ‘Founding 420’ in the month of January. Each member of the Founding 420 represents one of the Company’s first four-hundred and twenty clients. This bestows upon each member a number of benefits, including a welcome package with an Aurora-branded DaVinci Ascent portable vaporizer, a premium Aurora grinder, free cross-country shipping, and $50 in Aurora credit. In return, Aurora will be asking for detailed feedback with respect to the product, the service, the delivery, our brand and other key metrics.
Neil Belot, Chief Brand Officer, comments, “People have been eagerly waiting to experience the Aurora Standard, and the response from the community has been fantastic. The Founding 420 welcome package has been a big hit and everyone is wondering what we are up to for our next campaign; here is a hint – 710.”
Over the next several months, one of Aurora’s future strains availabile is poised to make global headlines. Facility Director, Joel Fuzat, explains why:
“In February 2016, Aurora intends to begin selling its flagship CBD cannabis strain. This groundbreaking development represents new heights in the field of medicinal marijuana in Canada. Our CBD-rich strain tested at over 25{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} CBD and just 1{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} THC by an independent third-party laboratory during the qualification run, which would make this the highest percentage CBD flower in Canada by a significant margin.”
Cannabidiol, also known as CBD, is a non-pyschoactive cannabinoid. To date, according to various medical studies it has shown promise as a treatment for chronic pain, seizures, epilepsy, multiple, sclerosis, anxiety, different forms of inflammation, and regulation of immune system functioning amongst others. Further studies are underway to explore its promise as an inhibitor of cancer cell growth.
Additionally, Aurora’s application for a Section 56 exemption to produce cannabis derivatives, such as CBD oil products, has been submitted to Health Canada for approval. In anticipation of the introduction of this new suite of products, Mr. Bryan Pyle, an expert in chromatographic separation and extraction, has been added to the Aurora team.
Aurora CEO, Terry Booth, says, “We are thrilled to have Bryan join us. His experience in high value plant metabolites is invaluable. Bryan will help to ensure standardization and consistency in all our extract-based products. The Aurora Standard continues to resonate with people and raise the bar for the industry as a whole.”
Terry Booth also commented, “Now that we shored up our cash position, we can execute on a number of key initiatives that will swiftly strengthen market share and likely bring us to profitability in the shortest time frame accomplished by any publicly traded Licensed Producer in the MMPR industry to date.”
About Aurora Cannabis Inc.
Aurora’s wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical marijuana pursuant to the Marihuana for Medical Purposes Regulations and operates a 55,200 square foot expandable state-of-the-art production facility in Alberta, Canada. Aurora’s wholly-owned subsidiary, Australis Capital Inc., is an active participant in the U.S. Cannabis market. Aurora is trading on the Canadian Securities Exchange under the trading symbol “ACB”.
- Published in Aurora Cannabis, News Home
Aurora Cannabis obtains $3-million loan
Aurora Cannabis obtains $3-million loan
– Momentum Public Relations – Jan. 27, 2016
Aurora Cannabis Inc. has closed a $3-million secured demand loan. The loan matures two years from the date of closing or on demand. The maturity date of the loan will be accelerated if the company raises new debt, equity or other forms of financing of a minimum of $7.5-million.
A fee of 3 per cent of the gross proceeds of the loan will be payable to the lender. In addition, the company will issue 300,000 share purchase warrants to the lender, exercisable into common shares at a price of 55 cents per share for a period of four years expiring Jan. 25, 2020. The expiry date of these warrants may be accelerated by the company if its shares reach an average closing price of at least $1.10 over a period of 30 days. If any of the warrants expire unexercised, the company shall settle the warrants in cash.
Aurora’s total debt, including the loan, will have a maximum blended interest rate of approximately 6.85 per cent. The net proceeds from the loan will be used for working capital.
The warrants and the common shares underlying the warrants will be subject to a statutory four-month hold period in accordance with applicable Canadian securities laws.
We seek Safe Harbor.
- Published in Aurora Cannabis, News Home
Aurora Cannabis increases financing to $4.5-million
Aurora Cannabis (ACB:CSE) Increases Financing to $4.5-million
Due to strong response from investors, Aurora Cannabis Inc.’s non-brokered private placement of units has been oversubscribed, and, as a result, the private placement has been increased from $3.5-million to a maximum of $4.5-million.
As previously announced, the company closed the first tranche of the private placement consisting of 3,250,755 units of the company at a price of 53 cents per unit for gross proceeds of $1,722,900.
All other terms of the private placement remain the same as set forth in the company’s news release dated Dec. 30, 2015. Each unit consists of one common share and one transferable common share purchase warrant. Each warrant will entitle the holder to purchase an additional common share of the company at a price of 66 cents per common share for a period of two years. The expiry date of the warrants may be accelerated by the company if its shares trade above $1.25 for 10 consecutive trading days.
We seek Safe Harbor.
- Published in Aurora Cannabis, News Home
Aurora Announces Exclusive Rights to Cannabis Inhaler
VANCOUVER, BRITISH COLUMBIA–(Marketwired – Nov. 5, 2015) – Aurora Cannabis Inc. (“Aurora” or the “Company”) (CSE:ACB)(OTCQB:ACBFF)(FRANKFURT:21P)(WKN:A1C4WM) is pleased to announce that it has entered into a letter of intent (“LOI”) for exclusive distribution rights to Mystabis, a revolutionary inhaler that provides pressurized metered doses of cannabis.
The terms of the arrangement allow Aurora sole Canadian distribution of the device. The ability to administer metered doses is something that both patients and the medical community have been waiting for eagerly. Without the use of any form of heat or combustion, this pressurized inhaler (“pMDI”) delivers exact quantities of cannabinoids in a manner that provides rapid medicinal effects while preserving the entourage effects of the cannabinoids and terpenoids. Physicians will find the delivery mechanism to be very familiar and will appreciate the precision controlled per dose delivery of both the THC and CBD dominant formulations.
Terry Booth, CEO, commented, “We are very excited to have the opportunity to bring what we believe to be a game-changing medical device to Canadians. Aurora’s scientists and our American partner scientists have conducted extensive research into the validity of this device and are confident that Health Canada, healthcare practitioners and patients are likely to recognize this easy-to-use delivery system as being amongst the safest, most consistent, and most reliable methods of effectively administering medical cannabis.”
The proposed transaction is subject to the completion of satisfactory due diligence. The finalized terms will be released upon closing of the definitive agreement.
Operations Update:
The Company is also pleased to provide an update of the status of its application to amend the license allowing for the sale of medical marijuana. The Company’s Chief Brand Officer, Neil Belot, commented, “As the Marihuana for Medical Purposes Regulation (“MMPR”) continues to evolve, Licensed Producers are being held to increasingly stringent standards by Health Canada, and Aurora welcomes the added scrutiny from the inspectors from Health Canada’s Regions and Programs Bureau who have been visiting the facility over the past few weeks. Aurora has been in continual dialogue with Health Canada’s Office of Medical Cannabis and is confident that these extra steps in the sales licencing process are in the best interest of Aurora shareholders, patients and the Office of Medical Cannabis. Our goal has always been to raise the bar for the medical cannabis industry in Canada and we are thrilled to be setting the new standards. Moving forward, we believe all Licenced Producers will be held to the same standards during their annual license renewal process and patients across the country will have an improved experience overall.”
About Aurora Cannabis Inc.
Aurora’s wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical marijuana pursuant to the Marihuana for Medical Purposes Regulations and operates a 55,200 square foot expandable state-of-the-art production facility in Alberta, Canada. Aurora’s wholly-owned subsidiary, Australis Capital Inc., seeks to be an active participant in the U.S. Cannabis market.
On behalf of the Board of Directors,
AURORA CANNABIS INC.
Terry Booth, CEO
Certain information contained in this news release, including information respecting the Company, the LOI, anticipated sales license approval, production capacity, production yields and other aspects of its anticipated future operations may be deemed “forward-looking”. All statements in this news release, other than statements of historical fact, that address events or developments that Aurora expects to occur, are “forward-looking information”. These statements relate to future events and reflect Aurora’s current expectations or beliefs and are based on information currently available to Aurora. Such forward looking information are based on the Company’s current operations, estimates, forecasts and projections and other factors and events that are not within the control of Aurora and there is no assurance they will prove to be correct. Forward-looking information is not a guarantee of future performance and actual results and future events could differ materially from those discussed in the forward-looking information. All of the forward-looking information contained in this news release is qualified by these cautionary statements. Although Aurora believes that the forward-looking information contained in this news release is based on reasonable assumptions, readers cannot be assured that actual results will be consistent with such statements. Accordingly, readers are cautioned against placing undue reliance on forward-looking information. Aurora expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, events or otherwise, except in accordance with applicable securities laws.
The CSE, securities commission or other regulatory authority has not reviewed, approved or disapproved the contents of this press release. We seek Safe Harbour.
Brayden Sutton
Director of Business Development
(604) 219-7104
brayden@auroramj.com
www.auroramj.com
- Published in Aurora Cannabis
InvestmentPitch Media Invites Investors to the TakeStock Alberta Investor Forum in Calgary on November 6th, 2015 – Video Hosted on InvestmentPitch.com
Vancouver, British Columbia–(Newsfile Corp. – October 30, 2015) – InvestmentPitch Media would like to invite investors to the TakeStock Alberta Investor Forum in Calgary on November 6th, to be held at the downtown Ramada Inn, 708 – 8th Avenue SW, from 10:00 am to 6:00 pm.
The full day event will include an exciting lineup of public and private companies across a wide range of industries.
For more details, please watch this video (click here). If this link is not enabled, please visit www.InvestmentPitch.comand enter “TakeStock” in the search box.
If you cannot view the video above, please visit:
http://www.investmentpitch.com/video/0_nhdm5rag/TakeStock-Alberta-Investor-Forum-in-Calgary–November-6th-2015
Feature speaker, Bruce Edgelow, VP Strategic Initiatives with ATB Corporate Financial Services, will appropriately discuss the energy market in his presentation entitled: “Energy Market Update – What a difference a Year Makes“.
Come meet senior company management from some of Alberta’s most attractive growth stocks across a wide range of industries, including the following:
Aurora Cannabis (CSE: ACB) (www.auroramj.com) – Aurora is a culture and community minded marijuana company that in February 2015 received a license to produce from Health Canada.
eQube Gaming, (TSXV: EQG) (www.eqube.com) – eQube is a leading provider of community and charitable gaming solutions for charitable and commercial gaming facilities. eQube has a majority market share of the Canadian regulated eBingo market, is the leading provider to the Irish digital bingo market and now operates the largest linked bingo game in Western Canada.
Foran Mining Corporation, (TSXV: FOM) (www.foranmining.com) – Foran a copper-zinc exploration and development company focused on the Hanson Lake Camp in east-central Saskatchewan, Canada.
Marapharm Ventures, (CSE: MDM) (www.marapharm.com) – Marapharm invests in emerging markets in the medical and recreational marijuana industry. The business model is to apply for and purchase licenses and facilities in strategic locations.
North Arrow Minerals, (TSXV: NAR) (www.northarrowminerals.com) – North Arrow is a Canadian based exploration company focused on the identification and evaluation of diamond exploration opportunities in Canada.
For more information or to register for this free event, please visit www.takestockab.com.
About InvestmentPitch Media
InvestmentPitch Media is arguably the largest producer and distributer of video content, primarily for small and mid-cap companies. The company specializes in producing short videos based on significant news releases, research reports and other content of interest to investors.
CONTACT:
InvestmentPitch.com
Barry Morgan, CFO
bmorgan@investmentpitch.com
- Published in Aurora Cannabis
Aurora Announces Completion of Pre-License Assessments by Health Canada, Receipt of Production License for Building Number 3 and other Updates
VANCOUVER, BRITISH COLUMBIA–(Marketwired – Oct. 1, 2015) – Aurora Cannabis Inc. (CSE:ACB)(FRANKFURT:21P)(WKN:A1C4WM)(OTCQB:ACBFF) (“Aurora” or the “Company”) is pleased to announce that on Friday, September 25, 2015, Health Canada inspectors from the Regions and Programs Bureau (“RAPB”) completed their latest assessments in response to three active section 29 license amendment applications. The assessment visit commenced on September 22, 2015.
On the same day, Aurora received approval for its Building Number 3 Production license under the Marihuana for Medical Purposes Regulations (“MMPR”). Aurora’s entire facility is now approved to produce dried medical cannabis.
Aurora anticipates receiving further news regarding the additional section 29 license amendment applications including the Cannabis Oil Production License and the Sale of Dried Marijuana License.
Terry Booth, CEO, commented: “Getting the building 3 confirmation so quickly after the inspection is a fantastic sign. We are looking forward to the issuance of our sales license and extraction license so we can provide Canadians high quality medical cannabis produced to the Aurora Standard.”
Australis Holdings LLP, a 50{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} subsidiary of Aurora, continues with the engineering and design on the Bellingham project. The preliminary drawings have been received and are being reviewed. Washington regulators announced plans to begin Phase 2 of their medical cannabis program including to once again accept license applications on October 12, 2015, for the first time since 2012.
About Aurora Cannabis Inc.
Aurora’s wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical marijuana pursuant to the Marihuana for Medical Purposes Regulations and operates a 55,200 square foot expandable state-of-the-art production facility in Alberta, Canada. Aurora’s wholly-owned subsidiary, Australis Capital Inc., seeks to be an active participant in the U.S. Cannabis market. Aurora is trading on the Canadian Securities Exchange under the trading symbol “ACB”.
On behalf of the Board of Directors,
AURORA CANNABIS INC.
Terry Booth, CEO
The CSE, securities commission or other regulatory authority has not reviewed, approved or disapproved the contents of this press release. We seek Safe Harbour.
Aurora Cannabis Inc.
Nilda Rivera
Investor Relations
Toll Free: 1-844-928-7672
nilda@auroramj.com
www.auroramj.com
- Published in Aurora Cannabis